Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKinsey
Baxter
Express Scripts
Johnson and Johnson
Harvard Business School
McKesson

Last Updated: January 23, 2020

DrugPatentWatch Database Preview

DALVANCE Drug Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Which patents cover Dalvance, and when can generic versions of Dalvance launch?

Dalvance is a drug marketed by Allergan and is included in one NDA. There are four patents protecting this drug.

This drug has fifty-seven patent family members in twenty countries.

The generic ingredient in DALVANCE is dalbavancin hydrochloride. One supplier is listed for this compound. Additional details are available on the dalbavancin hydrochloride profile page.

US ANDA Litigation and Generic Entry Outlook for Dalvance

Dalvance was eligible for patent challenges on May 23, 2018.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be May 23, 2024. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Start Trial

Summary for DALVANCE
Drug patent expirations by year for DALVANCE
Drug Prices for DALVANCE

See drug prices for DALVANCE

Generic Entry Opportunity Date for DALVANCE
Generic Entry Date for DALVANCE*:
Constraining patent/regulatory exclusivity:
GENERATING ANTIBIOTIC INCENTIVES NOW
NDA:
Dosage:
POWDER;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for DALVANCE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Wake Forest University Health SciencesPhase 4
Johns Hopkins UniversityPhase 4
Infectious Diseases Physicians, Inc.Phase 4

See all DALVANCE clinical trials

Pharmacology for DALVANCE
Synonyms for DALVANCE
247175-55-9
808UI9MS5K
a a-1
A-A-1
B0U42518WL
BI 397
BI-397
BI397
CHEBI:82721
CHEMBL3301669
CS-3579
D03640
Dalbavancin (USAN/INN)
Dalbavancin [USAN:INN:BAN]
dalbavancin B0
Dalvance (TN)
DB06219
HY-17586
KGPGQDLTDHGEGT-SZUNQUCBSA-N
MDL 63,397
MDL 64,397
MDL-64397
UNII-808UI9MS5K
UNII-808UI9MS5K component KGPGQDLTDHGEGT-SZUNQUCBSA-N
UNII-B0U42518WL
VER 001
VER001
VERO001
Zeven
Zeven (TN)

US Patents and Regulatory Information for DALVANCE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan DALVANCE dalbavancin hydrochloride POWDER;INTRAVENOUS 021883-001 May 23, 2014 RX Yes Yes   Start Trial   Start Trial   Start Trial
Allergan DALVANCE dalbavancin hydrochloride POWDER;INTRAVENOUS 021883-001 May 23, 2014 RX Yes Yes   Start Trial   Start Trial   Start Trial
Allergan DALVANCE dalbavancin hydrochloride POWDER;INTRAVENOUS 021883-001 May 23, 2014 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Allergan DALVANCE dalbavancin hydrochloride POWDER;INTRAVENOUS 021883-001 May 23, 2014 RX Yes Yes   Start Trial   Start Trial   Start Trial
Allergan DALVANCE dalbavancin hydrochloride POWDER;INTRAVENOUS 021883-001 May 23, 2014 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Allergan DALVANCE dalbavancin hydrochloride POWDER;INTRAVENOUS 021883-001 May 23, 2014 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Harvard Business School
McKinsey
Merck
Dow
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.